Skip to main content
SpringerLink
Log in

Chronisch obstruktive Lungenerkrankung

Extrafein gegen Exazerbationen

  • infopharm
  • Published:
Pneumo News Aims and scope

Patienten mit schwerer COPD und hohem Exazerbationsrisiko sollen laut GOLD-Leitlinien eine Kombitherapie aus inhalierbarem Kortikosteroid (ICS) und lang wirksamem Betamimetikum (LABA) erhalten. Den Erfolg prägen aber nicht allein die Wirkstoffe.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

1

Literatur

  1. GOLD Guidelines Update January 2014; www.goldcopd.org

  2. Wedzicha JA et al. Lancet 2007; 370: 786–96.

    Article  PubMed  Google Scholar 

  3. de Backer W et al. J Aerosol Med Pulm Drug Delivery 2010; 23: 137–48.

    Article  Google Scholar 

  4. Calverley PM et al. Respir Med 2010; 104:1858–68.

    Article  CAS  PubMed  Google Scholar 

  5. Singh D et al. BMC Pulmonary Medicine 2014; 14: 43.

    Article  PubMed Central  PubMed  Google Scholar 

  6. Wedzicha JA et al. Respir Med 2014; Jun 6.

Quelle

  • Roundtable „ICS bei COPD“, Frankfurt/M, 25.7.2014; Veranstalter: Chiesi.

Download references

Author information

Authors and Affiliations

  1. http://www.springermedizin.de

    Abdol A. Ameri

Authors
  1. Abdol A. Ameri
    View author publications

    You can also search for this author in PubMed Google Scholar

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Ameri, A.A. Extrafein gegen Exazerbationen. Pneumo News 7, 55 (2015). https://doi.org/10.1007/s15033-015-0078-y

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s15033-015-0078-y

Search

Navigation